Elan and Wyeth not to resume testing of Alzheimer drug
Elan and Wyeth have announced that they are not to resume further dosing of AN-1792, an experimental immunotherapeutic under development for the treatment of mild to moderate Alzheimer's disease.
In early January, Wyeth and Elan suspended all clinical dosing with AN-1792 in the exploratory Phase 2A study immediately after learning that four patients in France were reported to have experienced clinical signs consistent with inflammation in the central nervous system. Since the company halted dosing in January, eleven additional patients were reported with symptoms associated with CNS inflammation.
Elan and Wyeth said that no more patients will be treated with the drug, but patients will continue to be monitored to assess ongoing safety. All patients who were reported with symptoms of CNS inflammation have received medical care and most have shown improvement or recovered.
